Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis

Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment combined with glycoprotein IIb/IIIa inhibitor for patients with STEMI undergoing PCI: a meta-analysis

Abstract Background For patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), the efficacy and safety of novel P2Y12 antagonists, including prasugrel or ticagrelor, has not been established relative to that of the clopidogrel-based trip...

Full description

Bibliographic Details
Main Authors: Zhe Wang, Da-Yan Zhou, Yong Su, Liang-Yi Si, Qiang Xu
Format: Article
Language:English
Published: BMC 2020-03-01
Series:BMC Cardiovascular Disorders
Subjects:
Prasugrel
Ticagrelor
Glycoprotein IIb/IIIa inhibitor
ST segment elevation myocardial infarction
Meta-analysis
Online Access:http://link.springer.com/article/10.1186/s12872-020-01403-6

Similar Items

Similar Items